Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stargardt Macular Dystrophy: early-phase trial registry
3 of 4 indexed Stargardt Macular Dystrophy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Stargardt Macular Dystrophy: 4 US clinical trials tracked, 3 recruiting.
Stargardt Macular Dystrophy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Alkeus Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition stargardt-macular-dystrophy
OPEN 3 | RECR 75% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Stargardt Macular Dystrophy lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stargardt Macular Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stargardt Macular Dystrophy is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Ray Therapeutics
NCT06375239
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Astellas Pharma Global Development
NCT07425574
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Splice Bio
NCT06942572
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Alkeus Pharmaceuticals
NCT04239625
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stargardt Macular Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stargardt Macular Dystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stargardt Macular Dystrophy page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Stargardt Macular Dystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alkeus Pharmaceuticals sponsors the most Stargardt Macular Dystrophy trials on record, review their full trial history before evaluating a specific study. See Alkeus Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stargardt Macular Dystrophy condition card totals 4 registered trials; most-linked intervention ALK-001; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.